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Abstract 21 
The swift spread of infections caused by drug-resistant bacteria, such as methicillin-resistant 22 
Staphylococcus aureus (MRSA), has quickly become a worldwide concern as infections spread 23 
from healthcare settings to the wider community. While ferrocenyl chalcones, which are 24 
chalcone derivatives with antimicrobial activity, have gained attention from researchers, 25 
further study is needed to assess their cytotoxicity. Ten newly developed chalcones, in which 26 
ring A was replaced with a ferrocenyl moiety and ring B contained increasing alkyl chain 27 
lengths from 5-10 carbons, were assessed. Using 2-fold broth microdilution, the minimum 28 
inhibitory concentration (MIC) of five of the ten compounds were lower against Gram-positive 29 
organisms (MICs from 0.008 mg/ml to 0.063 mg/ml) than Gram-negative organisms (MICs = 30 
0.125 mg/ml). These novel ferrocenyl chalcone compounds were effective against 3 types of 31 
clinically isolated drug-resistant S. aureus, including a MRSA, and against other non-resistant 32 
clinically isolated and laboratory-adapted Gram-positive bacteria. The same compounds 33 
inhibited growth in non-resistant bacteria by potentially obstructing cellular respiration in 34 
Gram-positive bacteria. Images obtained through scanning electron microscopy revealed fully 35 
lysed bacterial cells once exposed to a selected compound that showed activity. The results 36 
indicate that these newly developed compounds could be important antimicrobial agents in 37 
the treatment of infections from clinically resistant bacteria. 38 
Keywords: Antimicrobial agents/antimicrobial drug resistance/cellular 39 
respiration/chalcones/mechanism of action/scanning electron microscopy 40 
 41 
 42 
 43 
 44 
 45 
 46 
 47 
 48 
3 
 
Introduction 49 
The increasing resistance of microorganisms to antibacterial agents is a global threat to public health 50 
and the over-prescription and misuse of antibacterial drugs have been identified as key factors in the 51 
development of bacterial antibiotic resistance [1]. In 2019, the World Health Organisation (WHO) 52 
published a working paper, which outlined the implementation and coordination of six strategies for 53 
a successful approach towards combatting antimicrobial resistance [2]. 54 
Resistance in bacteria can be influenced by the minimum inhibitory concentration (MIC) of a 55 
particular antibiotic at lethal or, more often, at sub-lethal levels. Bacteria that select for resistance 56 
because of sub-lethal antibiotic levels may use various mechanisms of drug resistance including 57 
mutations in bacterial genes responsible for antimicrobial susceptibility, which may be integrated or 58 
transferable [3], or mutations in efflux pumps in bacterial cells [4]. Lack of bioavailability leading to 59 
low blood and tissue levels can lead to suboptimal drug exposure leading to microbes becoming 60 
resistant. Raising dose levels could lead to enhanced toxicity and adverse events [5], [6].  61 
The initial  focus of the prevalence of antimicrobial drug resistance was limited to nosocomial  62 
infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and glycopeptide-resistant 63 
Enterococci (GRE) but similar infections began to emerge in the community and  in non-clinical 64 
environments [7]. Subsequently, the WHO [8] reported the existence of other multidrug-resistant 65 
(MDR) bacteria including carbapenemase-producing Enterobacteriaceae (CPE), the most common 66 
being Klebsiella pneumoniae and Escherichia coli [9]. A report by Allegranzi et al. [10] indicated that 67 
MDR-associated nosocomial infections in developing countries (15.5 per 100 patients) were higher 68 
than the mean incidence in European health institutions (7.1 per 100 patients) because of unsafe 69 
surgeries that may include surgical instruments contaminated with resistant bacteria. This increased 70 
risk suggests the need for greater scrutiny of surgical procedures and related infection control 71 
practices. 72 
The emergence of CPEs has prompted an increase in the use of colistin (polymixin E), which is 73 
considered to be the ‘last line of defence’ and is a critical agent against some common multidrug-74 
resistant Gram-negative aerobic bacilli, including CPEs. The mechanism of action of colistin is to 75 
damage the integrity of the outer envelope of Gram-negative bacilli by causing instability of 76 
membrane-bound lipopolysaccharides (LPS) [11]. This damage allows cellular contents to escape, 77 
resulting in apoptosis but the  toxic effects of colistin on the human kidney prevented  its use in 78 
routine antimicrobial therapy [12]. Overuse of colistin has now resulted in infections caused by 79 
colistin-resistant CPEs. Initially, resistance was thought to result from chromosomal mutations but 80 
recent reports have shown that resistance can be mediated by the transfer of plasmids containing 81 
the colistin-resistant gene known as MCR-1 [13]. A 2016 report by the European Centre for Disease 82 
Prevention and Control (ECDC) described infections caused by this type of colistin resistance as a 83 
critical public health issue [14]. 84 
Even as resistance to available antibacterial agents increases, the number of new, effective agents 85 
being discovered particularly for Gram-negative infections remains small [15]. Poor financial returns 86 
of approved antibiotics, combined with a reduction of regulatory approval for new drugs to treat 87 
drug-resistant bacteria, has affected progress in the development of new antibiotics [16], [17]. A 88 
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clear  need exists for development of novel antibacterial drugs with increased efficacy, particularly 89 
against infections caused by MDR Gram-negative organisms [18]. 90 
Chalcones 91 
One avenue of research into antimicrobial drug development is the use of flavonoids [19]. These 92 
organic compounds, synthesised by plants, contribute to the colour in flowers making them alluring 93 
to pollinators, increase survival by protecting them from fungal infection and ultra violet radiation, 94 
and are involved in essential cellular processes such as energy transfer, respiration and 95 
photosynthesis [19]. Another key role is as an antioxidant. Chalcones (Figure 3), a class of flavonoids, 96 
have attracted the attention of researchers as they show reduced cytotoxicity to humans and 97 
increased antibacterial potency [19]. Specifically, ferrocene-containing chalcones have been shown 98 
to be attractive potential antimicrobial agents due to their favourable characteristics such as 99 
lipophilicity and ease of chemical modification [20] suggesting that they may also be potential 100 
scaffold molecules for other new potent antimicrobial drugs [19], [21]–[24].  101 
Ferrocenyl chalcones 102 
Researchers are focussed on ferrocene-type drugs because of their benefits such as their small size, 103 
comparative lipophilicity, a key feature allowing diffusion across cell membranes, ease of chemical 104 
modification, as mentioned above, and accessible one-electron-oxidation potential. Classes of 105 
ferrocenyl chalcones are primarily of two types, as seen in Figure 1; Type 1 where the carbonyl group 106 
is at the α-position adjacent to the ferrocenyl ring and Type 2 where the carbonyl group is at the α-107 
position adjacent to the phenyl ring. 108 
However, these compounds require further study to determine their efficacy and any possible 109 
toxicity to mammalian cells [20].  110 
Ferrocenyl chalcones have been altered to produce sulfones [25]. These sulphur-based compounds 111 
were synthesized using the meta-chloroperbenzoic acid, catalysed oxidation of ferrocenyl chalcone 112 
sulfides (Figure 2). Much like the ferrocenyl chalcone derivatives used in the current study, several of 113 
the compounds described by Ahmed et al. reportedly inhibited bacterial growth at minimum 114 
inhibitory concentrations (MIC) lower than amikacin and ampicillin [26]. 115 
The research described in this paper involved the testing of novel functionalised ferrocenyl 116 
chalcones (Chart 1). The overall synthesis of these Type 2 ferrocenyl chalcones, which were 117 
produced by Crouch [27], are shown in Figure 3. 118 
The lipophilicity of these compounds increased as alkyl chain length of the R group increased (from 119 
methyl to decyl). In the current study, the antimicrobial activity of these highly lipophilic chemicals 120 
were investigated as well as their mode(s) of action, which possibly involved the reduction of 121 
bacterial cell viability. 122 
The newly developed ferrocenyl chalcones used in this study will be investigated to determine if one 123 
potential mechanism was to block bacterial dehydrogenases involved in respiration, which would 124 
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interrupt the bacterial electron transport chain necessary for energy and growth as described by 125 
Haddock & Jones [28]. The current study used 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 126 
bromide (MTT) to indicate bacterial cell viability in terms of the amount of formazan product formed 127 
[29]. In actively respiring cells, these respiratory dehydrogenases were considered to reduce the 128 
yellow MTT compound to insoluble purple formazan [30]. The MTT assay is an inexpensive method 129 
that has been used to demonstrate inhibition of bacterial cell respiration as an indicator of cell 130 
viability of Escherichia coli [31] and Mycobacterium tuberculosis H37Rv [29]. Inhibition of this vital 131 
cellular process can result in cellular lysis. 132 
Scanning electron microscopy (SEM) was used to gain images to obtain an insight into possible 133 
external morphological changes to the cells. These changes could include visible pores on the 134 
envelope like that seen in antimicrobial peptide activity against E. coli 25922 and Staphylococcus 135 
aureus 25923 [32], or fully lysed cells like those seen in the treatment of Bacillus cereus with sucrose 136 
monocaprate [33]. 137 
 Aims and objectives 138 
The principle aim of this study was to identify any antimicrobial activity of the ferrocenyl chalcone 139 
derivatives on non-resistant laboratory-adapted bacteria, followed by identifying if there was also 140 
antimicrobial activity against a panel of drug-resistant and non-resistant clinical isolates from the 141 
Royal Chesterfield Hospital, UK. The organisms used in the current study were selected based on 142 
availability and to represent a broad spectrum of bacteria. The proposed method was based on the 143 
2-fold broth microdilution method described by Andrews [34]. Another aim of the current study was 144 
to determine the potential mechanism of action of the ferrocenyl chalcone derivatives using MTT 145 
assay as described by Moodley et al. [29]. Finally, the project aimed to obtain micrographic evidence 146 
of possible external damage to bacterial cells that may result from exposure to these compounds 147 
using SEM as detailed by Hartmann et al. [32]. 148 
Material and Methods 149 
Preparation of ferrocenyl chalcones and control antibiotics 150 
Ferrocenyl chalcones of increasing alkyl chain lengths (methyl to decyl) were provided by Crouch 151 
[27]. Fresh stock solutions of each compound were prepared at 1 mg/ml in dimethyl sulfoxide 152 
(DMSO) (Alfa Aesar, Lancashire, UK) for each assay. Stock 250 mg/ml antibiotic solutions of 153 
penicillin-G (Sigma, Dorset, UK) and oxytetracycline were prepared in sterile deionised water 154 
according to the standard method described by Andrews [34]. Each solution was divided into 1 ml 155 
aliquots in sterile microcentrifuge tubes and then stored at -20oC. 156 
Preparation of inocula 157 
Inocula of S. aureus NCIMB 8244, E. faecalis NCTC 12697, K. kristinae NCIMB 8884, E. coli NCIMB 158 
9483, K. pneumoniae (IH) and Salmonella serotype Manchester NCTC 7832 were prepared by 159 
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suspending at least 3-4 colonies of each organism into individual sterile 10 ml aliquots of sterile 160 
Oxoid MH broth (Fisher Scientific, Loughborough, UK) and incubated for 15-20 minutes at 37oC in air 161 
while stirring. Suspensions were diluted 1:100 in sterile MH broth to gain starting inocula of 105 per 162 
BSAC standards. Clinical isolates of non-resistant E. coli, S. aureus, resistant S. aureus (penicillin; 163 
erythromycin, penicillin, clindamycin) and a MRSA were prepared as described in the previous 164 
sentence. K. kristinae NCIMB 8884 were prepared 1:10 also per BSAC standards. 165 
Minimum inhibitory concentration assay 166 
Minimum inhibitory concentrations (MICs) were determined using 2-fold serial broth microdilution 167 
of each ferrocenyl chalcone compound with sterile MH broth. Each prepared inoculum (75 µl) was 168 
added to equal volumes of diluted ferrocenyl chalcone solution in Nunc 0.2 ml flat bottom 96-well 169 
12-column microtitre plates (Fisher Scientific, Loughborough, UK). This was repeated for each 170 
ferrocenyl chalcone compound. Column 11 was treated with antibiotic (penicillin-G and 171 
oxytetracycline) and column 12 was left untreated. Plates were then incubated at 37oC for 18-24 172 
hours. Absorbance values were measured using a Rosys Anthos 2010 microplate reader (Salzberg, 173 
Austria) at 620 nm adapted from Medu [35].  174 
Bacterial MTT assay 175 
Bacterial cell viability of resistant and non-resistant bacteria at MIC was determined by inoculating 176 
96-well microplates as described above, followed by the addition of 10 µl of MTT solution (5 mg/ml) 177 
(Sigma-Aldrich, Dorset, UK). Plates were incubated at room temperature for 3 hours followed by 178 
addition of 50 µl of DMSO. Absorbance values were measured at 570 nm. 179 
Bacterial Scanning Electron Microscopy (SEM) 180 
Treated non-resistant bacteria, S. aureus NCIMB 8244, K. kristinae NCIMB 8884 and E. faecalis NCTC 181 
12697 were exposed to decyl ferrocenyl chalcone solution at MIC value and incubated for 18-24 182 
hours at 37oC, whilst untreated cells were incubated under the same conditions in the absence of 183 
chalcone. Treated and untreated cells were incubated with 2%   w/v glutaraldehyde for 1 hour then 184 
washed with sterile phosphate buffer saline (PBS) by centrifugation [32]. The cells were then 185 
dehydrated with a graded series of ethanol (20% v/v, 40% v/v, 60% v/v, 80% v/v, 95% v/v, 100% v/v, 186 
100% v/v, 100% v/v) and re-suspended in sterile deionised water. Re-suspended cells (10 µl) were 187 
pipetted on to 0.2 µm Cyclopore Track Etch polycarbonate membrane filter discs (Whatman 188 
International Limited, Maidstone, UK) and sputter-coated with gold. Secondary electron images 189 
were taken using the JEOL JSM 6610V SEM (Herts, UK). 190 
Statistical analysis 191 
The Kolmogorov-Smirnoff test was used to determine data normality of the MTT assay data. 192 
Statistical analysis of the MTT assay data in the study was performed using a One-Way ANOVA to 193 
determine if the mean percentage of actively respiring cells differed between the hexyl to decyl 194 
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ferrocenyl chalcones treatments.  195 
Results  196 
MIC assay 197 
Methyl to pentyl ferrocenyl chalcones showed lower antimicrobial activity than hexyl to decyl 198 
ferrocenyl chalcones (Table 1). The former group of compounds showed MIC values of 0.125 mg/ml 199 
(± 0.000) for all organisms tested. MIC values at 0.125 mg/ml contained 12.5% v/v DMSO, which was 200 
the threshold at which microbial growth was seen. The chalcones with longer alkyl chain lengths 201 
(hexyl-decyl) also had lower MICs against Gram-positive bacteria than against Gram-negative 202 
bacteria. MIC of these compounds with longer alkyl chains ranged from 0.008 mg/ml (± 0.000) and 203 
0.063 mg/ml (± 0.000) for S. aureus NCIMB 8244, E. faecalis NCTC 12697, K. kristinae NCIMB 8884 204 
and a non-resistant clinical isolate of S. aureus, while MICs against all Gram-negatives = 0.125 mg/ml 205 
(± 0.000). MICs for the same longer alkyl chain ferrocenyl chalcones against resistant clinical isolates 206 
range of S. aureus from 0.031 mg/ml (± 0.000) to 0.063 mg/ml (± 0.000). No growth was observed 207 
with organisms that were treated with penicillin-G or oxytetracycline at an MIC of 0.125 mg/ml.   208 
MTT assay 209 
The results of the MTT assay of non-resistant Gram-positive laboratory organisms demonstrated 210 
that the percentage of actively respiring cells, in terms of formazan product observed (Figure 4) 211 
decreased after exposure to chalcones at the MIC value. No viable cells (mean estimated percentage 212 
of 0%) were seen for S. aureus NCIMB 8244 when exposed to hexyl and octyl, for K. kristinae NCIMB 213 
8884 after exposure to hexyl and heptyl, and for E. faecalis NCTC 12697 when exposed to hexyl and 214 
heptyl. The highest percentage was measured for S. aureus NCIMB 8244 after incubation with decyl 215 
(4.241%). 216 
In the MTT assay of resistant and non-resistant Gram-positive clinical isolates the percentage of 217 
actively respiring cells, in terms of formazan product observed (Figure 5) also decreased after 218 
exposure to chalcones at the MIC value. No viable cells (mean percentage of 0%) were seen for fully 219 
sensitive S. aureus (RCH) when exposed to hexyl, heptyl and octyl, for PEN-resistant S. aureus (RCH) 220 
when exposed to heptyl, octyl, nonyl and decyl, for PEN/ERY/CLI-resistant S. aureus (RCH) and MRSA 221 
when exposed to hexyl, heptyl, nonyl and decyl. The highest percentage was determined for fully 222 
sensitive S. aureus (RCH) after incubation with nonyl (2.242%). 223 
There were no significant differences at p=0.05 between these chalcones (hexyl to decyl), in terms of 224 
mean percentage (±SD) of actively respiring cells present, against S. aureus NCIMB 8244 (p=0.107), 225 
K. kristinae NCIMB 8884 (p=0.326) and E. faecalis NCTC 12697 (p=0.118). Similarly, there were no 226 
significant differences between these compounds against fully sensitive S. aureus (RCH) (p=0.523), 227 
penicillin-resistant S. aureus (RCH) (p=0.418), PEN-, ERY-, CLI-resistant S. aureus (RCH) (p=0.418) and 228 
a MRSA (RCH) (p=0.418). 229 
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Bacterial SEM 230 
The SEM images (Figures 6A-F) revealed that exposure to decyl ferrocenyl chalcone resulted in 231 
morphological changes to bacterial cells at MIC. The affected cells appeared fully lysed, while 232 
unaffected cells maintained their spherical or spherical-like (opioid) appearance. 233 
Discussion 234 
In the broth microdilution assay, fresh DMSO was used as the solvent for the ferrocenyl chalcones. 235 
The results showed that MIC values of the methyl to pentyl ferrocenyl chalcone compounds (0.125 236 
mg/ml in 12.5% v/v DMSO ) were within the reported values for penicillin (0.000015-0.128 mg/ml) 237 
against Staphylococci [34]. In the same assay, the MIC values of all 10 compounds were 0.125 mg/ml 238 
in 12.5% v/v DMSO against Enterobacteriaceae, which were within the values reported by Andrews 239 
[34] for tetracycline (0.00025-0.128 mg/ml) against Enterobacteriaceae. These values were used 240 
since oxytetracycline is an analogue of tetracycline. However, growth inhibition may also have 241 
resulted from exposure of the organisms to DMSO. DMSO has been shown to have an inhibitory 242 
effect at percentages equal to and/or greater than 12.5% v/v [36]. This was confirmed in a 243 
simultaneous study but not reported in the current paper.  The chalcone MIC values for S. aureus 244 
NCIMB 8244 began to decrease as alkyl chain length increased.  This was especially seen with hexyl 245 
to nonyl (0.063 mg/ml) and decyl (0.031 mg/ml). Except for hexyl against clinically isolated S. aureus 246 
(fully sensitive) (RCH), sensitivity was also seen for hexyl to decyl against penicillin-resistant S. aureus 247 
(RCH), penicillin-, erythromycin-, clindamycin-resistant S. aureus clinical isolates (RCH) (0.031 mg/ml 248 
to 0.063 mg/ml). No growth was observed with organisms that were treated with approximately 249 
0.125 mg/ml of known control antibiotics, which were within the reported MIC range of penicillin 250 
and tetracycline [34]. 251 
The MIC values reported in Table 1 varied between each organism and between each chalcone. 252 
When used against S. pyogenes NCIMB 8884, which was later confirmed to be K. kristinae, all 253 
chalcones with longer alkyl chains showed MIC values of 0.016 mg/ml except for hexyl (0.031 254 
mg/ml) and heptyl (0.008 mg/ml). When used against E. faecalis NCTC 12697, hexyl to decyl 255 
ferrocenyl chalcones showed MIC values of 0.063 mg/ml. These values were also within the 256 
expected range (0.0005-0.128 mg/ml) for Enterococci [34]. Although antimicrobial activity was seen 257 
with hexyl to decyl against K. pneumoniae (IH), E. coli (RCH), E. coli NCIMB 9483 and Salmonella 258 
“Manchester” NCTC 7372 (0.125 mg/ml), it may have resulted from sensitivity to 12.5% v/v DMSO. 259 
The overall trend appeared to be that the chalcones had a greater inhibitory effect on Gram-positive 260 
bacteria than on Gram-negative bacteria. The difference in MIC values with respect to the Gram-261 
negative and Gram-positive organisms may be because of increasing alkyl chain length. One 262 
explanation why the Gram reaction may have been a factor was that the compounds may have 263 
passed across the thick hydrophilic peptidoglycan layer of Gram-positive bacteria because of the 264 
amphipathic DMSO [37]. The long chains may have become trapped in the cell membrane allowing 265 
the attached ferrocenyl groups, which were relatively smaller than the alkyl chains, to enter the 266 
cytoplasm. Since Gram-negative bacteria have outer envelopes with membrane transporter proteins 267 
such as porins, followed by thin peptidoglycan layers and cell membranes in their cellular envelopes, 268 
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entry into these cells may have been more difficult. These porins would have allowed hydrophilic 269 
compounds to enter, while hydrophobic compounds may have diffused across the lipid bilayer of the 270 
outer envelope [38]. However, because of the fluidity of the outer lipid bilayer of Gram-negative 271 
bacteria, the long alkyl chains of the ferrocenyl chalcones may have become trapped in the outer 272 
envelope and would have been unable to cross the peptidoglycan layer and cell membrane into the 273 
cells. Another reason why the difference between Gram-negative and Gram-positive bacteria may 274 
have been important was that organisms such as E. coli had become used to living in enriched 275 
media, which promoted vigorous growth [39].  276 
The MIC values of the ferrocenyl chalcones against the organisms used in this study corresponded 277 
with the percentage of actively respiring cells in terms of the formazan product seen. This suggests 278 
that the metabolic process used to convert MTT, as discussed by Riss et al. [30], was not active at the 279 
concentrations of chalcones present in the cells. Therefore, little or no formazan product was 280 
detected at 570 nm on the microplate reader. In the MTT assay involving Gram-negative bacteria, 281 
growth inhibition, which was seen at 0.125 mg/ml, may also have resulted from exposure of the 282 
organisms to DMSO. This implies that the percentage of viable cells that were involved in MTT 283 
metabolism to formazan were very low at the assessed MIC. 284 
When compared to MTT screening of ferrocenyl chalcone antimicrobial activity against 285 
Mycobacterium tuberculosis, the MIC values in this study lay within the reported range (0.016-0.128 286 
mg/ml) [29], except for K. kristinae where a lower MIC (heptyl chalcone) was used. In the microplate 287 
assays, the overall trend showed that the chalcones had a greater inhibitory effect on Gram-288 
positives than on Gram-negatives. The trend also indicated that there were no significant differences 289 
between the chalcones with longer alkyl chains (hexyl to decyl) in terms of mean percentage (±SD) of 290 
actively respiring cells present against S. aureus NCIMB 8244, K. kristinae NCIMB 8884 and E. faecalis 291 
NCTC 12697. Thus, the compounds were equally effective at inhibiting respiration in bacterial cells. 292 
Similarly, the chalcones were equally effective at respiration inhibition for fully sensitive S. aureus 293 
(RCH), penicillin-resistant S. aureus (RCH), PEN-, ERY-, CLI-resistant S. aureus (RCH) and a MRSA 294 
(RCH). Increased chain length may have allowed the ferrocene groups to enter the cytoplasm of 295 
Gram-positive organisms. Ferrocene groups have been proposed to be inhibitors of cellular 296 
respiration, in which the ferrocene groups act as uncouplers [20]. Since Gram-negative organisms 297 
possess outer envelopes, thin peptidoglycan layers with increased periplasmic space and cell 298 
membranes in their cell envelopes, entry into these cells may be more difficult. Another possibility 299 
was that the cell membrane of Gram-positive bacteria was compromised such that the electron 300 
transport chain cannot function [28]. Cell viability, as indicated by MTT metabolism to formazan, 301 
decreased in Gram-positives when compared to Gram-negatives. Therefore, a possible mechanism 302 
of action of the chalcones with longer alkyl chain lengths may have been inhibition of cellular 303 
respiration. 304 
Visible effects of possible inhibition of cellular respiration were seen in micrographs of bacterial 305 
samples (Figures 6B, 6D & 6F) at MIC, where the cells exhibited lysis when treated with decyl 306 
ferrocenyl chalcone. In contrast, untreated S. aureus NCIMB 8244, K. kristinae NCIMB 8884 and E. 307 
faecalis NCTC 12697 appeared unaffected externally (Figure 6A, 6C & 6E). This potential mode of 308 
action was proposed based on observations of similar cellular damage caused by respiration 309 
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inhibitors when S. aureus ATCC 25923 was exposed to graphene films on three types of conductors 310 
[40] and when S. aureus RSSK01009 were exposed to essential oil terpenes [41]. 311 
This spread is in part caused by the misuse of antibiotics and the unavailability of new drugs. This is 312 
the first report to demonstrate that ferrocenyl chalcones, which can be structurally altered by 313 
synthetic methods, possess significant antimicrobial activity against non-resistant lab organisms and 314 
resistant and non-resistant clinical isolates. This study also indicates that activity was potentially 315 
characterised by interference of bacterial respiration. The findings of this study reveal that these 316 
novel ferrocenyl chalcone compounds are potential antimicrobial agents against clinical bacterial 317 
isolates requiring further investigation. 318 
In order to progress the possible use of ferrocenyl chalcones alkyl iodide chains as promising 319 
alternative antimicrobial drugs, future research into these current chemicals, which includes their 320 
effects against biofilms and mammalian cells. Further assays involving the efficacy of the compounds 321 
against biofilms, such as a comparable study reported by Kunthalert et al. [42], and cytotoxicity 322 
against mammalian cells, such as a similar study reported by Kowalski et al. [43] are needed to 323 
strengthen the profile of the ferrocenyl chalcone compounds. 324 
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Table 1– Minimum Inhibitory Concentration values (mg/ml) of methyl to decyl ferrocenyl chalcone compounds against non-resistant and 
resistant lab isolates and clinical isolates. RCH = Royal Chesterfield Hospital; IH = Ian Hopkins; PEN= penicillin; ERY = erythromycin; CLI = 
clindamycin; MRSA = methicillin-resistant S. aureus. 
Organism Mean (±0.000, n=6) MIC (mg/ml) 
Methyl Ethyl Propyl Butyl Pentyl Hexyl Heptyl Octyl Nonyl Decyl 
S. aureus NCIMB 8244 0.125 0.125 0.125 0.125 0.125 0.063 0.063 0.063 0.063 0.031 
K. kristinae NCIMB 8884 0.125 0.125 0.125 0.125 0.125 0.031 0.008 0.016 0.016 0.016 
E. faecalis NCTC 12697 0.125 0.125 0.125 0.125 0.125 0.063 0.063 0.063 0.063 0.063 
S. aureus Fully Sens. (RCH) - - - - - 0.125 0.063 0.063 0.063 0.063 
PEN-resistant S. aureus (RCH) - - - - - 0.063 0.031 0.063 0.063 0.063 
PEN-, ERY-, CLI-resistant (RCH) - - - - - 0.063 0.031 0.063 0.063 0.063 
MRSA (RCH) - - - - - 0.063 0.063 0.063 0.063 0.063 
E. coli NCIMB 9483 0.125 0.125 0.125 0.125 0.125 0.125 0.125 0.125 0.125 0.125 
K. pneumoniae (IH) 0.125 0.125 0.125 0.125 0.125 0.125 0.125 0.125 0.125 0.125 
Salmonella "Manchester" NCTC 7372 0.125 0.125 0.125 0.125 0.125 0.125 0.125 0.125 0.125 0.125 
E. coli Fully Sens. (RCH) - - - - - 0.125 0.125 0.125 0.125 0.125 
 
 
 
Figure 4 - Estimated percentage of actively respiring non-resistant lab bacterial cells when 
treated with ferrocenyl chalcone at MIC. Box plots represent the lower and upper quartiles 
with the medians shown as black lines. Whiskers represent the minimum and maximum 
percentages and each X represents the mean values. 
 
 
Figure 5 - Estimated percentage of actively respiring resistant and non-resistant clinically 
isolated bacterial cells when treated with ferrocenyl chalcone at MIC. Box plots represent the 
lower and upper quartiles with the medians shown as black lines. Whiskers represent the 
minimum and maximum percentages and each X represents the mean values. 
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Figure 6 – SEM images: A) untreated S. aureus NCIMB 8244 (dotted arrows indicate some of the 
cells with spherical appearance); B) treated S. aureus NCIMB 8244 (dotted arrow indicates an 
unaffected cell and solid arrows indicate some of the fully lysed cells at MIC 0.031 mg/ml); C) 
untreated K. kristinae NCIMB 8244 (dotted arrows indicate some of the cells with spherical 
appearance and double-lined arrow indicates a dividing cell); D) treated K. kristinae NCIMB 8884 
(solid arrows indicate some of the fully lysed cells at MIC 0.016 mg/ml); E) untreated E. faecalis 
NCTC 12697 (dotted arrows indicate some of the cells with normal appearance); F) treated E. 
faecalis NCTC 12697 (solid arrows indicate some of the severely damaged cells at MIC 0.063 
mg/ml). 
 
